Abrocitinib

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Eczema

Conditions

Eczema

Trial Timeline

Jul 24, 2025 → May 2, 2027

NCT ID

NCT06807268

About Abrocitinib

Abrocitinib is a phase 3 stage product being developed by Pfizer for Eczema. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06807268. Target conditions include Eczema.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04564755	Pre-clinical	Completed	—	—	Atopic Dermatitis
NCT05466578	Pre-clinical	Active	—	—	Severe Uncontrolled Atopic Dermatitis
NCT06899204	Pre-clinical	Recruiting	Jan 13, 2026	Sep 30, 2026	Atopic Dermatitis
NCT06807281	Phase 3	Recruiting	Dec 2, 2025	Feb 22, 2032	Atopic Dermatitis
NCT06807268	Phase 3	Recruiting	Jul 24, 2025	May 2, 2027	Eczema
NCT05721937	Pre-clinical	Recruiting	Jul 25, 2023	Dec 31, 2027	Atopic Dermatitis
NCT05689151	Pre-clinical	Recruiting	Mar 9, 2023	Dec 31, 2027	Atopic Dermatitis
NCT05391061	Pre-clinical	Recruiting	Jan 7, 2023	Nov 22, 2027	Dermatitis, Atopic
NCT05038982	Phase 2	Completed	Sep 9, 2021	Jul 11, 2022	Prurigo Nodularis

Competing Products

20 competing products in Eczema

See all competitors

Product	Company	Stage	Hype Score
1% Colloidal Oatmeal Balm	Johnson & Johnson	Pre-clinical	23
Colloidal Oatmeal Cream	Johnson & Johnson	Phase 3	77
Pimecrolimus cream 1%	Novartis	Approved	85
Dupilumab + Placebo	Sanofi	Phase 2	51
Amlitelimab + Placebo	Sanofi	Phase 2	51
alitretinoin + Placebo	GSK plc	Phase 3	76
Dupilumab	Regeneron Pharmaceuticals	Approved	84
Adventan® (methylprednisolone aceponate 0,1%)	Bayer	Phase 1	30
Ruxolitinib cream + Vehicle	Incyte	Phase 3	74
Ruxolitinib cream + Vehicle	Incyte	Phase 2	49
Ruxolitinib cream + Vehicle	Incyte	Phase 3	74
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Arcutis Biotherapeutics	Phase 3	72
Roflumilast Cream + Vehicle cream	Arcutis Biotherapeutics	Phase 3	72
ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 2	47
Roflumilast Cream 0.05% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	72
Roflumilast Cream 0.15% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	72
ARQ-151 cream 0.15% + ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 1	28
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	36
LAS41003 + LAS189962 + LAS189961	Almirall	Phase 2	47
LAS 41002 + Active	Almirall	Phase 2	47

Other Products from Pfizer